Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EPS Creative Health Technology Group (HKSE:03860) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
EPS Creative Health Technology Group EBITDA Margin % Related Terms
EPS Creative Health Technology Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS Creative Health Technology Group EBITDA Margin % Chart
HKSE:03860 vs TJX, ROST, BURL: EBITDA Margin % Comparison
For the Apparel Retail subindustry, EPS Creative Health Technology Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EPS Creative Health Technology Group EBITDA Margin % vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, EPS Creative Health Technology Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where EPS Creative Health Technology Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS Creative Health Technology Group (HKSE:03860) has a EBITDA Margin % of 1.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EPS Creative Health Technology Group and its competitors. This is 37% below median its historical median of 3.00. According to the industry distribution chart, EPS Creative Health Technology Group ranks #783 out of 1126 companies in the Retail - Cyclical industry, placing it in the top 69.5%.
Is EPS Creative Health Technology Group's EBITDA Margin % too high?
EPS Creative Health Technology Group's current EBITDA Margin % of 1.90% is 37% below median its 10-year median of 3.00. The Retail - Cyclical industry median EBITDA Margin % is 7.50. EPS Creative Health Technology Group's value of 1.90% is 74.6% below this industry median. Based on the distribution chart, EPS Creative Health Technology Group ranks #783 out of 1126 companies in the Retail - Cyclical industry, which is below the industry midpoint. Overall, EPS Creative Health Technology Group has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EPS Creative Health Technology Group's EBITDA Margin % compare to TJX and ROST?
According to the Retail - Cyclical industry distribution chart, EPS Creative Health Technology Group ranks #783 out of 1126 companies for EBITDA Margin %. This places EPS Creative Health Technology Group in the lower half of its industry. The industry median EBITDA Margin % is 7.50. EPS Creative Health Technology Group's value of 1.90% is 74.6% below this benchmark. While the company's 10-year median is 3.00 vs. the industry median of 7.50, EPS Creative Health Technology Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Retail - Cyclical company?
The median EBITDA Margin % among Retail - Cyclical companies is 7.50, based on 1,126 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EPS Creative Health Technology Group's current EBITDA Margin % of 1.90% is 74.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EPS Creative Health Technology Group and its competitors. For the Retail - Cyclical industry, the median EBITDA Margin % is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EPS Creative Health Technology Group's current EBITDA Margin % is 1.90%, which is 37% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EPS Creative Health Technology Group stock overvalued right now?
Based on GuruFocus' analysis, EPS Creative Health Technology Group (HKSE:03860) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.59, compared to a current price of HK$0.63 — trading 6.8% above its estimated fair value. The current EBITDA Margin % is 1.90%, which is 37% below median its 10-year median of 3.00 and 74.6% below the Retail - Cyclical industry median of 7.50. EPS Creative Health Technology Group's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For EPS Creative Health Technology Group (HKSE:03860), the current EBITDA Margin % is 1.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EPS Creative Health Technology Group (HKSE:03860) Overvalued in 2026?
Based on GuruFocus' analysis, EPS Creative Health Technology Group stock appears to be overvalued.
The current stock price of HK$0.63 is trading 6.8% above its estimated GF Value™ of HK$0.59.
GuruFocus considers EPS Creative Health Technology Group to be Fairly Valued.
Key valuation signals for HKSE:03860:
EBITDA Margin %: 1.90% (37% below median its 10-year median of 3.00)
GF Value™: HK$0.59 vs. price of HK$0.63 (6.8% above fair value)
Industry Position: 74.6% below the Retail - Cyclical median (#783 of 1126)
No single metric tells the full story. See the HKSE:03860 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EPS Creative Health Technology Group Ltd is an investment holding company. Its segment includes the Garment business, Healthcare Products Business, and IRO with CRO and In-House R&D Business. It generates maximum revenue from the Garment segment which includes the provision of apparel supply chain management services for knitwear apparel products. Geographically, it derives a majority of revenue from Japan and also has its presence in Hong Kong, Mainland China, Europe, United States and Other Countries.
56GF Score
Get the complete analysis for HKSE:03860
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03860 has been successfully added to your 
